Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 µg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7) pg/ml (P<0.001) but not on nonparicalcitol therapy. At 6 months, levels significantly differed between treatments (P<0.001 by analysis of covariance). Serum bone-specific alkaline phosphatase and osteocalcin decreased on paricalcitol therapy only and significantly differed between treatments at 6 months (P<0.001 for all comparisons). At 6 months, urinary deoxypyridinoline-to-creatinine ratio and 24-hour proteinuria level decreased only on paricalcitol (P<0.05). L3 and L4 vertebral mineral bone density, assessed by dual-energy x-ray absorption, significantly improved with paricalcitol at 6 months (P<0.05 for both densities). Paricalcitol was well tolerated. Overall, 6-month paricalcitol supplementation reduced parathyroid hormone levels and proteinuria, attenuated bone remodeling and mineral loss, and reduced eGFR in renal transplant recipients with secondary hyperparathyroidism. Long-term studies are needed to monitor directly measured GFR, ensure that the bone remodeling and mineral effects are sustained, and determine if the reduction in proteinuria improves renal and cardiovascular outcomes.
AuthorsMatias Trillini, Monica Cortinovis, Piero Ruggenenti, Jorge Reyes Loaeza, Karen Courville, Claudia Ferrer-Siles, Silvia Prandini, Flavio Gaspari, Antonio Cannata, Alessandro Villa, Annalisa Perna, Eliana Gotti, Maria Rosa Caruso, Davide Martinetti, Giuseppe Remuzzi, Norberto Perico
JournalJournal of the American Society of Nephrology : JASN (J Am Soc Nephrol) Vol. 26 Issue 5 Pg. 1205-14 (May 2015) ISSN: 1533-3450 [Electronic] United States
PMID25194004 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 by the American Society of Nephrology.
Chemical References
  • Bone Density Conservation Agents
  • Ergocalciferols
  • Parathyroid Hormone
  • Phosphates
  • Vitamin D
  • paricalcitol
  • Creatinine
  • Calcium
  • Adult
  • Bone Density (drug effects)
  • Bone Density Conservation Agents (pharmacology, therapeutic use)
  • Bone Remodeling (drug effects)
  • Calcium (blood)
  • Creatinine (blood)
  • Cross-Over Studies
  • Ergocalciferols (pharmacology, therapeutic use)
  • Female
  • Humans
  • Hyperparathyroidism, Secondary (blood, drug therapy)
  • Kidney Transplantation
  • Male
  • Middle Aged
  • Parathyroid Hormone (blood)
  • Phosphates (blood)
  • Postoperative Complications (blood, drug therapy)
  • Prospective Studies
  • Proteinuria (drug therapy)
  • Vitamin D (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: